facebook twitter linkedin
rd offer

This material was prepared by a third party towards Selvita S.A. with its registered office in Kraków (hereunder: “Selvita”). Within the scope which was not authorized by Selvita’s management board, the description of factual circumstances regarding the activities of Selvita, embodied in this material presents merely opinion of the third party, in particular with respect to presented opinions, predictions, appraisals and forecasts of the financial data and future activity of Selvita and its results.

Therefore, Selvita does not warrant consistency of this material with the actual and legal situation. Neither Selvita, members of its corporate bodies, employees nor its consultants shall bear any liability for validity of opinions, predictions, appraisals, forecasts and any other date embodied in this material as well as for consequences of actions of any reader made on a basis of this material, in particular for the investment decisions or any losses resulting from use of this material.

Readers of this material shall make its own assessment, whether opinions or forecasts embodied therein are credible and adequate, in particular taking into account their investment strategy and actual and legal situation. In particular they should consult it with their independent financial and investment advisors. None of the information presented in this material shall constitute investment, legal, accounting or tax advice or a statement that any investment strategy is accurate or adequate, considering the circumstances of the reader.

Furthermore date presented in this material shall not constitute an offer to sell or purchase any financial instruments nor an invite the make such offer. It shall not be also not deemed as a recommendation for investment in any financial instrument nor an advertisement of such instruments.


Cancer metabolism platform

Selvita is currently running two cancer metabolism collaborations. The aim of these projects run within cancer metabolism platform is development of new anticancer drugs acting on biological targets associated with aberrant metabolic pathways in cancer cells (cancer metabolism). Dependence on specific metabolic pathways (e.g. glutaminolysis or glycolysis) is a feature of various types of cancer, therefore, targeting this vulnerability has potentially very broad application.

In October 2013, within the platform, Selvita started a strategic partnership with Merck KGaA (Germany). Jointly initiated research strategy assumed intensive development within several chemical series. The main goal of the project is to characterize a series of lead molecules with the proven mechanism of action and as the final step selection of candidates for further preclinical development.